A patent is an option: a call option, premium already paid, that goes to zero at expiry

In an earlier piece I said a patent is "an asset whose value goes to zero at maturity." When I tell that story, people who know finance tend to slap their knees.

"Wait, isn't that exactly an 'option'?"

It is. The structure of a patent closely resembles a derivative called an "option." Today let's read patents in the language of options. The "payoff" part in particular should be fun.

1What is an option? A "right" you can exercise in the future, and an expiry

An option is a "right," not an "obligation." Take a call option: it is the "right to buy" an asset at a set price in the future. If it is favorable, you exercise it. If not, you simply let it go.

An option comes down to two things.

• It has an expiration date.
• If it has not become favorable by expiry, the option becomes "waste paper" → worth zero.

In other words, an option is a right you either "use (exercise) or abandon (let lapse)."

2Patent = an option with an expiry

A patent is exactly the same.

• A patent is a "right to monopolize a market." (It is not an obligation. You may commercialize it, or not.)
• It has an "expiry": the 20-year term.
• When that expiry passes, the right lapses and its value goes to "zero," just as an option becomes waste paper at expiry.

If the market grows, you "exercise" the patent (commercialization, licensing, litigation) and capture a large value. If there is no market, it reaches expiry unexercised and goes to zero. This is why so many patents lie dormant: most options lapse "without ever being exercised."

3Asymmetric payoff: losses are capped, gains are open

The real reason options are attractive is their "asymmetric payoff."

[ Payoff profile for the buyer of a call option ]

• Below break-even → the loss is fixed at "the premium already paid" (it cannot get worse)
• Above break-even → the higher it goes, the larger the gain (open to the upside)

In a word: "the loss is fixed and the gain is open." That is the magic of options.

• Worst case → you lose the development, filing and maintenance costs. But the loss stops there; it is "capped."
• Best case → if the patent dominates a market, the return can be tens or hundreds of times the input. It is "open" to the upside.

That is why patents (and R&D) are "like a lottery, but rational." Most lapse to zero, but when one hits, it more than covers all the other failures. Venture investing and drug development run on the same principle.

4The premium: options charge it "separately," patents have "already" paid it

To buy an option you have to pay a "premium" (the option price). What about patents?

In other words, the moment you develop and register a patent, you have already paid the "option premium." That amount is reflected on the books (in its price) as the patent's acquisition cost.

So holding a patent is like holding "a 20-year call option whose premium is already paid." Only one question remains: "Will a market arrive in which to exercise this option before it expires?"

5That makes a patent a "real option"

Finance theory has a concept called the "real option," which treats real investments as options. Patents are a textbook case.

• Time-value decay → as expiry approaches, an option's "time value" shrinks (theta). A patent's option value likewise falls as its remaining term shortens. (This connects to duration in the "Maturity" piece.)
• A portfolio approach → most individual options lapse. So you hold many and design it so one big hit covers the whole. This is exactly what a patent portfolio strategy is.

6So how to manage patents as "options"

• Exercise before expiry: since it goes to zero at expiry, "exercise" it through commercialization, licensing or sale when the market arrives.
• Use the asymmetry: with losses capped, plant several options in technologies with large upside.
• Protect time value: the remaining term is the option value. Do not let it sleep; move while there is still time.

Closing: the loss is already paid, the gain is still open

A patent is an "option." It goes to zero after expiry (20 years) (lapse at expiry), its losses are capped and its gains are open (asymmetric payoff), and its premium has already been paid through R&D (a call option already paid for).

For this option to remain an "exercisable right" before expiry, though, the right itself must be strong. If it is invalidated or designed around, it cannot be exercised no matter how big the market gets. That is why reading the option's value is my job (finance), and protecting the right so the option stays exercisable is the job of attorney Yoo Yeon (law).

"A patent is a call option with the premium already paid. The loss is already paid and the gain is still open. All that remains is to exercise it before expiry."